Literature DB >> 12673411

Clinical analysis of pulmonary Mycobacterium avium complex disease in association with corticosteroid treatment.

Yoshihiro Kobashi1, Toshiharu Matsushima.   

Abstract

We studied the clinical characteristics of nine patients with pulmonary Mycobacterium avium complex disease occurring in association with corticosteroid drugs collected from our associated hospitals during the past 6 years. The average age of the nine patients was 62.2 years and the male/female ratio was 3 : 6. Regarding underlying disease, respiratory diseases existed in four of the patients and nonrespiratory diseases in the other five patients. The duration of corticosteroid treatment ranged from 5 months to 5 years, and the total dose of corticosteroid drugs ranged from 1.78 to 43.20 g. Pulmonary Mycobacterium avium complex disease was detected by clinical symptoms during corticosteroid treatment in six patients, and purified protein derivative was positive in three of eight patients tested. Radiological findings showed an infiltration shadow without cavity and bronchiectasis in the lower lung field. Microbiological examination was smear-positive in three patients, and the isolated mycobacterium was Mycobacterium intracellulare in five patients and Mycobacterium avium in four. Tolerance was shown to all antituberculous drugs, except for clarithromycin, in all patients. Although treatment including clarithromycin was performed for seven patients, the sputum conversion rate was 33% and an improved clinical effect was noted in only one patient. No change occurred in four and worsening occurred in four. Attention should be paid to the clinical symptoms and radiological findings of patients who have received corticosteroid drugs over a long period of time, because pulmonary Mycobacterium avium complex is characterized by atypical radiographic findings with no relationship to the total dose or duration of the administered corticosteroid drugs.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12673411     DOI: 10.1007/s10156-002-0216-4

Source DB:  PubMed          Journal:  J Infect Chemother        ISSN: 1341-321X            Impact factor:   2.211


  4 in total

1.  Cloning and characterization of CYP51 from Mycobacterium avium.

Authors:  Michael P Pietila; Pawan K Vohra; Bharati Sanyal; Nancy L Wengenack; Sreekumar Raghavakaimal; Charles F Thomas
Journal:  Am J Respir Cell Mol Biol       Date:  2006-03-16       Impact factor: 6.914

2.  The first US domestic report of disseminated Mycobacterium avium complex and anti-interferon-γ autoantibodies.

Authors:  Elise O'Connell; Lindsey B Rosen; Richard W LaRue; Valeria Fabre; Michael T Melia; Paul G Auwaerter; Steven M Holland; Sarah K Browne
Journal:  J Clin Immunol       Date:  2014-08-23       Impact factor: 8.542

3.  Successful treatment with mepolizumab in a case of allergic bronchopulmonary aspergillosis complicated with nontuberculous mycobacterial infection.

Authors:  Hironobu Tsubouchi; Shinpei Tsuchida; Shigehisa Yanagi; Takafumi Shigekusa; Mariko Miura; Kenjiro Sakaguchi; Nobuhiro Matsumoto; Masamitsu Nakazato
Journal:  Respir Med Case Rep       Date:  2019-06-05

Review 4.  The New Frontier of Host-Directed Therapies for Mycobacterium avium Complex.

Authors:  Nathan P Crilly; Samuel K Ayeh; Petros C Karakousis
Journal:  Front Immunol       Date:  2021-01-22       Impact factor: 7.561

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.